We are live on ! Find out more
ARRY icon

Array Biopharma
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

128 hedge funds and large institutions have $447M invested in Array Biopharma in 2013 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

58.43% more ownership

Funds ownership: 0% → 58.43% (+58%)

51% less call options, than puts

Call options by funds: $396K | Put options by funds: $809K

Holders
128
Holders Change
+128
Holders Change %
–
% of All Funds
4.16%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.13%
New
–
Increased
–
Reduced
–
Closed
–
Calls
$396​K
Puts
$809​K
Net Calls
-⁠$413​K
Net Calls Change
-⁠$413​K

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

ARRY Hedge Fund Activity: Q2 2013 in Review

128 of the 3,075 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma (ARRY) for Q2 2013, worth a combined $447M.

Fund positioning in ARRY was balanced in Q2 2013: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 128 institutional investors held Array Biopharma (ARRY) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $447M of Array Biopharma stock for Q2 2013.
  • 0 funds opened new Array Biopharma positions in Q2 2013 and 0 closed out.

Based on aggregated 13F filings for Q2 2013.